42 / 53
Phase 2 Study of Lorlatinib in Patients With
Advanced ALK
+
/ROS1
+
Non-Small Cell Lung Cancer
Benjamin J. Solomon,
1
Alice T. Shaw,
2
Sai-Hong I. Ou,
3
Benjamin Besse,
4
Enriqueta Felip,
5
Todd M. Bauer,
6
Ross A. Soo,
7
Alessandra Bearz,
8
Chia-Chi Lin,
9
Jill S. Clancy,
10
Antonello Abbattista,
11
Holger Thurm,
12
Gerson Peltz,
13
Elizabeth T. Masters,
14
Jean-François Martini,
12
Leonard P. James,
14
Takashi Seto
15
1
Peter MacCallum Cancer Centre, Melbourne, Australia;
2
Massachusetts General Hospital, Boston, MA, USA;
3
University of California Irvine,
Irvine, CA, USA;
4
Gustave Roussy Cancer Campus, Villejuif, France, and Paris-Sud University, Orsay, France;
5
Vall d’Hebron Institute of
Oncology, Barcelona, Spain;
6
Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA;
7
National University
Hospital Singapore, Singapore;
8
National Cancer Institute, Aviano, Italy;
9
Taipei Medical University, Taipei, Taiwan;
10
Inventiv Clinical,
Princeton, NJ, USA;
11
Pfizer Oncology, Milan, Italy;
12
Pfizer Oncology, La Jolla, CA, USA;
13
Pfizer Oncology, Groton, CT, USA;
14
Pfizer Oncology, New York, NY, USA;
15
National Kyushu Cancer Center, Fukuoka, Japan